Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

120.91
-1.2531-1.03%
Post-market: 120.910.00000.00%16:10 EDT
Volume:16.66K
Turnover:2.01M
Market Cap:102.77M
PE:- -
High:123.15
Open:123.15
Low:118.50
Close:122.16
52wk High:126.40
52wk Low:54.56
Shares:850.00K
Float Shares:850.00K
Volume Ratio:0.72
T/O Rate:1.96%
Dividend:0.32
Dividend Rate:0.26%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amgen Exec Says Continues to Expect Capital Expenditures of About $2.6 Billion in 2026 to Scale Manufacturing Capacity, Including for Maritide's Launch

THOMSON REUTERS
·
Aug 05

Amgen Exec Says Expect a Meaningful Sequential Increase in Operating Expenses in the Third Quarter

THOMSON REUTERS
·
Aug 05

Amgen Exec Says Spent $500 Million in Q2 on Capital Expenditures, Driven by Investments Across United States Manufacturing Sites-Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Saw a Softer Hiv Treatment Market in Q2 as People Fell Out of Insurance Plans Due to Eliminated Aca Tax Subsidies - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Raising Full Year Hiv Growth Expectations to 9%-10% Year-over-Year from Prior Guidance of 8% Growth - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Launch Preparations Fully Underway for Anito-Cel Cell Therapy, with Five Months to Go Until FDA Pdufa Date - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Do not Currently Anticipate Pursuing Additional Sizable M&a Transactions This Year - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Amgen Q2 FY26 GAAP EPS Rises 65% to $4.37; Revenue Increases 10% to $10.1 Billion

Reuters
·
Aug 05

Amgen Inc Stock (AMGN) Closed Up by 3.03% on Aug 4: Key Drivers Unveiled

TradingKey
·
Aug 05

Gilead Sciences Inc Q2 Adjusted EPS USD -6.75 Vs. IBES Estimate USD -7.24

Reuters
·
Aug 05

Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story

Dow Jones
·
Aug 05

Gilead Q2 FY26 Loss Per Share Widens to $(8.45); Revenue Rises 10% to $7.8 Billion

Reuters
·
Aug 05

GUIDANCE: (GILD) Gilead Sciences Expects Full Year 2026 Adjusted Loss Range of $0.30 - $0.65, vs. FactSet Est of $0.75 Loss

MT Newswires Live
·
Aug 05

Amgen Second-Quarter Sales Rise 9%, Profit Tops Street View

Reuters
·
Aug 05

Gilead Second-Quarter Sales Rise 8%, Beating Wall Street Estimates

Reuters
·
Aug 05

Gilead: Qtrly Adj EPS $-6.75 Reflecting $-9.08 Per Share Acquired Ipr&D and Tax Expenses Associated with Recent Acquisitions

THOMSON REUTERS
·
Aug 05

Gilead Sciences Inc Q2 Product Sales USD 7,627 Million

THOMSON REUTERS
·
Aug 05

Amgen Outlook FY Revenue USD 38,200-39,400 Million

THOMSON REUTERS
·
Aug 05

Amgen Inc: a Phase 1 Study of Amg 513 in Adults Living with Obesity Will Remain Ongoing

THOMSON REUTERS
·
Aug 05